Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04660643 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 783
- Enrollment target
NCT04660643 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 783 participants.
The verdict
NCT04660643, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 783 participants
- Enrollment target
Study Summary
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Interventions
- DRUG Tirzepatide
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 783 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04660643
The ClinicalTrials.gov registry entry for NCT04660643 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 783 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT04660643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04660643 about?
NCT04660643 is a clinical study titled "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss". This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either co...
What is the current status of trial NCT04660643?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 783 participants. The study started on 2021-03-29. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT04660643?
The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT04660643?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.